Hepatitis B Annual
Home

Current Issue  

Back Issues   

Instructions   

Search Login    Users online: 258 Print this page  Email this page Small font sizeDefault font sizeIncrease font size 
>>> Ahead of Print <<<
REVIEW ARTICLE
Year : 2006  |  Volume : 3  |  Issue : 1  |  Page : 35-53

Entecavir : A review


Department of Gastroenterology and Hepatology, Singapore General Hospital, Singapore

Correspondence Address:
Chee-Kiat Tan
Department of Gastroenterology and Hepatology, Singapore General Hospital, Outram Road 169608
Singapore
Login to access the Email id

Source of Support: None, Conflict of Interest: None


Rights and PermissionsRights and Permissions

Entecavir is the newest and most potent nucleoside analog to be licensed worldwide for the treatment of chronic hepatitis B infection. It has been shown to be more effective than lamivudine and adefovir in direct head-to-head comparison trials. It is also useful in the treatment of lamivudine-refractory patients. Entecavir is safe with no significant difference in adverse effects compared to lamivudine and adefovir. Available data for up to 2 years of continuous therapy showed no development of viral resistance in nucleos(t)ide-naοve patients. Resistance to entecavir occurs only in patients previously exposed to lamivudine and occurs at a rate of 9% after 2 years of continuous therapy with entecavir.


[FULL TEXT] [PDF]*
Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed15789    
    Printed515    
    Emailed1    
    PDF Downloaded633    
    Comments [Add]    

Recommend this journal